scientific programme
42
thursday, 26 June 2014
S-31
SYMPOSIUM
09:00–11:00
Ballroom A
Track: Translational
Topic: Depression (A)
Polypharmacy in psychotic and affective
disorders: Co-medication with antipsy-
chotic and antidepressant drugs
Chair:
Hans-Jürgen Möller, Germany
Co-Chair: Barbara J. Sahakian, United
Kingdom
S-31-001
Treatment of negative vs. other symptoms
in schizophrenia
Hans-Jürgen Möller, Germany
S-31-002
Concomitant antidepressant and antipsy-
chotic medication in schizophrenia and de-
pression. Mechanisms of action
Torgny Svensson, Sweden
S-31-003
The role of atypical antipsychotics as add-on
medication in major depression
Siegfried Kasper, Austria
S-31-004
Cognitive dysfunction in depression: Impli-
cations for treatment
Barbara J. Sahakian, United Kingdom
Learning Objectives:
This symposium will dis-
cuss the use of polypharmacy in psychotic and
affective disorders with a focus on whether and
how antipsychotic and antidepressant drugs
can be used as co-medications.
S-32
SYMPOSIUM
09:00–11:00
Ballroom B
Track: Basic
Topic: Schizophrenia (A)
New insights into the role of NMDA re-
ceptors in cognition and psychosis
Chair:
Andrew Holmes, USA
Co-Chair: Stan Floresco, Canada
S-32-001
NMDA-GluN2B receptors govern corticos-
triatal learning
Andrew Holmes, USA
S-32-002
NMDA receptor-associated proteins, cogni-
tion, and neuropsychiatric disorders: Trans-
lation between mouse and human
Tim Bussey, United Kingdom
S-32-003
NMDA receptors and behavioural flexibility:
For when things aren‘t the way they used 2B
Stan Floresco, Canada
S-32-004
The human ketamine model: Translational
insights into psychosis
Philip R. Corlett, USA
Learning Objectives:
With the increased re
cognition of the behavioural outcomes from
the use of ketamine, an NMDA receptor
blocker, this symposium will review the role
of NMDA receptors in cognition and psychosis.
S-33
SYMPOSIUM
09:00–11:00
Ballroom C
Track: Translational
Topic: Biomarkers (including pharmacoge-
nomics and brain imaging) for diagnosis
and treatment response (C)
Converting biological findings into rou-
tine clinical tests – Psychiatry‘s next big
challenge
Chair:
Shitij Kapur, United Kingdom
Co-Chair: Roy Perlis, USA
S-33-001
Converting biological psychiatry into clini-
cal tests – why it has been so hard and what
to do about it
Andrea Mechelli, United Kingdom
S-33-002
Clinical significance: What does it mean
when developing biomarker and clinical
tests for treatment response in depression
and schizophrenia
Rudolf Uher, Canada
S-33-003
From pharmacogenetics to clinical tests: The
role of electronic health records
Roy Perlis, USA
S-33-004
Pharmacogenomic tests for psychotropic
medications – a journey from bench to bed-
side
Tony Altar, USA
Learning Objectives:
This symposium will
address the challenges in converting biologi-
cal findings around psychiatric disorders into
routine clinical tests.
